Stage II gastric cancer: 1 year of S-1 remains standard of care Editorial
| Author: | Ilson, D. H. |
| Title: | Stage II gastric cancer: 1 year of S-1 remains standard of care |
| Keywords: | treatment outcome; cancer recurrence; treatment duration; note; capecitabine; cancer adjuvant therapy; postoperative care; cancer staging; neuropathy; docetaxel; health care quality; microsatellite instability; gastrectomy; stomach cancer; oxaliplatin; esophageal adenocarcinoma; pyrimidine; recurrence free survival; phase 3 clinical trial (topic); gastrointestinal carcinoma; gimeracil plus oteracil potassium plus tegafur; cancer prognosis; human; priority journal; doxifluridine |
| Journal Title: | The Lancet Gastroenterology & Hepatology |
| Volume: | 4 |
| Issue: | 3 |
| ISSN: | 2468-1253 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2019-03-01 |
| Start Page: | 188 |
| End Page: | 189 |
| Language: | English |
| DOI: | 10.1016/s2468-1253(18)30411-4 |
| PUBMED: | 30679110 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Source: Scopus |
